Inhibitory Activities of Dimeric Ellagitannins Isolated from Cornus alba on Benign Prostatic Hypertrophy.

Dong-Hui Park,Kyung-Mi Kim,Hyun-Joo Chung,Min-Won Lee,Jun-Hyeok Heo,Min-Ji Kim,Kwan-Hee Park,Jin-Wook Kim,Jun Yin,Sun-Ho Lee,Seong-Eun Yoon

doi:10.3390/molecules26113446

Dong-Hui Park, Kyung-Mi Kim + Show 9 more

Open Access

https://doi.org/10.3390/molecules26113446

Copy DOI

Abstract

Benign prostatic hypertrophy (BPH) is an intractable chronic inflammatory disease. We studied the efficacy of two ellagitannins, namely camptothin B (1) and cornusiin A (2) that were isolated from Cornus alba (CA) for the treatment of BPH, which is a common health issue in older men. The ellagitannins (1 and 2) were evaluated on its inhibitory activities of the enzyme 5α-reductase and tumor necrosis factor (TNF)-α, its interleukin (IL)-1β, IL-6, and IL-8 production, and its anti-proliferation and apoptosis induction in prostate cells that show hypertrophy (RWPE-1 cell). In inhibition of 5α-reductase, the ellagitannins (1 and 2) showed potential effects, compared to the positive control, finasteride. In the case of IL-1β, IL-6, IL-8, and TNF-α, 1 and 2 showed good inhibitory effects as compared to the control group treated with LPS. The ellagitannins (1 and 2) were also shown to inhibit proliferation of, and induce apoptosis in, the RWPE-1 cell. These results suggest that the ellagitannins (1 and 2) may be good candidates for the treatment of BPH.

Highlights

Benign prostatic hypertrophy (BPH), a type of overgrowth of the prostate tissue, is a common problem in older men
The cause of BPH is unclear, studies have suggested that the common factors that might induce the development of BPH are hormonal alterations, ageing, and inflammation [6,7]
BPH is caused by the influence of dihydrotestosterone (DHT), which is known to be a testosterone derivative with a high affinity for androgen receptors [8]

Summary

Introduction

Benign prostatic hypertrophy (BPH), a type of overgrowth of the prostate tissue, is a common problem in older men. Studies have reported that prostatic growth begins at age 30, with BPH affecting approximately 50% of men aged 50 and 70% of men older than 80 [4,5]. The medications used to treat BPH include alpha-blockers and 5-alpha reductase inhibitors (5-ARI) [8]. Alpha blockers treat the symptoms of BPH by relaxing the smooth muscle tissue in the prostate and bladder to help the urine flow out. It has no effect on prostate growth through its mechanism of action, and can quickly heal symptoms of the lower urinary tract [9]. Unlike the alpha blocker, which improves relatively quickly, 5-ARI takes a long time to contract the prostate [10]

Methods

Findings

Discussion

Conclusion